Asmanex now OK for younger children with asthma
Mometasone powder approved for younger children
The Schering-Plough Corp., is now approved for the maintenance treatment of asthma as a preventative therapy in patients ages four to 11 years old. Containing mometasone furoate inhalation powder, the new inhaler was previously approved as a
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Recent Videos
